AstraZeneca gastrointestinal news

The First Chamber of the European Court of Justice dismissed an appeal from AstraZeneca following a 2010 ruling by the General Court of the European Union regarding gastrointestinal drugs Losec/ Prilosec omeprazole. The 2010 ruling followed a decision from the European Commission in 2005 that the company and its AstraZeneca AB subsidiary prevented the sale of generic versions of Losec. The commission said the companies made misleading representations before several European patent offices to obtain and defend Supplementary Protection Certificates for the product, as well as selective deregistration of marketing authorizations in Denmark, Norway and Sweden, followed by the withdrawal from the market of Losec capsules and the launch of Losec Multi Unit Pellet System (MUPS) tablets in those countries. In its ruling, the General Court issued a €12.3 million €($15.8 million) fine to AstraZeneca AB, in addition to the €40.3 million ($52 million) fine that was imposed on the pharma. AstraZeneca said in a comment that it is "disappointed" with the decision. ...